azelastine has been researched along with Allergic Rhinitis in 28 studies
azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia
azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis." | 9.51 | A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial. ( Alyasin, S; Babaeian, M; Esmaeilzadeh, H; Far, NM; Hadipour, M; Nabavizadeh, SH, 2022) |
| "Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis." | 9.01 | Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis. ( Bareiss, AK; Debbaneh, PM; McCoul, ED; Wise, SK, 2019) |
| "A retrospective study was conducted to investigate the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis (AR) and the effects of CCL26 and CC chemokine receptor-3 (CCR3)." | 8.31 | Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels. ( Liu, S; Liu, Y; Lu, SF; Zang, GM, 2023) |
| "Azelastine hydrochloride (azelastine) nasal spray is a histamine receptor-1 (H1) antagonist often used in treating allergic rhinitis to relieve its symptoms." | 7.91 | Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis. ( Cheng, LH; Chu, YH; Lee, JC; Lin, YY; Wang, HW; Wu, PC, 2019) |
| "The effect of cinnamaldehyde on the treatment of allergic rhinitis (AR) was investigated in rat model." | 7.83 | Cinnamaldehyde is an effective anti-inflammatory agent for treatment of allergic rhinitis in a rat model. ( Altun, H; Cengiz, BP; Çetinkaya, EA; Cingi, C; Hancı, D; Muluk, NB, 2016) |
| "We investigated the antioxidant effects of curcumin in an experimental rat model of allergic rhinitis (AR)." | 7.83 | Antioxidant activities of curcumin in allergic rhinitis. ( Acar, M; Altıntoprak, N; Berkoz, M; Cingi, C; Kar, M; Muluk, NB, 2016) |
| "Twenty-eight male Wistar albino rats were randomly divided into four groups: a control group; a group in which allergic rhinitis was induced and no treatment given; a group in which allergic rhinitis was induced followed by treatment with azelastine hydrochloride on days 21-28; and a group in which allergic rhinitis was induced followed by treatment with curcumin on days 21-28." | 7.83 | Can curcumin modulate allergic rhinitis in rats? ( Acar, M; Ada, S; Berkoz, M; Cengiz, BP; Cingi, C; Karimkhani, H; Muluk, NB; Shojaolsadati, P; Yigitaslan, S, 2016) |
| "Azelastine was suggested as a supplementary choice of glucocorticoid for the control of moderate to severe allergic rhinitis (AR)." | 7.81 | Azelastine enhances the clinical efficacy of glucocorticoid by modulating MKP-1 expression in allergic rhinitis. ( Li, H; Li, J; Luo, X; Ma, R; Mou, Z; Wu, X; Xian, D, 2015) |
| "Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis." | 5.51 | A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial. ( Alyasin, S; Babaeian, M; Esmaeilzadeh, H; Far, NM; Hadipour, M; Nabavizadeh, SH, 2022) |
| "The safety of a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) has been established in adults and adolescents with allergic rhinitis but not in children <12 years old." | 5.27 | Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. ( Berger, W; Fineman, S; Gawchik, S; Sher, E, 2018) |
| "Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis." | 5.01 | Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis. ( Bareiss, AK; Debbaneh, PM; McCoul, ED; Wise, SK, 2019) |
| "A retrospective study was conducted to investigate the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis (AR) and the effects of CCL26 and CC chemokine receptor-3 (CCR3)." | 4.31 | Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels. ( Liu, S; Liu, Y; Lu, SF; Zang, GM, 2023) |
| "Azelastine hydrochloride (azelastine) nasal spray is a histamine receptor-1 (H1) antagonist often used in treating allergic rhinitis to relieve its symptoms." | 3.91 | Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis. ( Cheng, LH; Chu, YH; Lee, JC; Lin, YY; Wang, HW; Wu, PC, 2019) |
| "The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu (Dymista, a novel formulation of azelastine hydrochloride, fluticasone propionate and excipients in a single spray) in real life in the UK and physicians' reasons for prescribing it and (2) to quantify the personal and societal burden of allergic rhinitis (AR) in the UK prior to MP-AzeFlu prescription." | 3.85 | Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. ( Ahmed, S; El-Shanawany, T; Kumar, N; Price, D; Ray, J; Sargur, R; Scadding, G, 2017) |
| "The effect of cinnamaldehyde on the treatment of allergic rhinitis (AR) was investigated in rat model." | 3.83 | Cinnamaldehyde is an effective anti-inflammatory agent for treatment of allergic rhinitis in a rat model. ( Altun, H; Cengiz, BP; Çetinkaya, EA; Cingi, C; Hancı, D; Muluk, NB, 2016) |
| "We investigated the antioxidant effects of curcumin in an experimental rat model of allergic rhinitis (AR)." | 3.83 | Antioxidant activities of curcumin in allergic rhinitis. ( Acar, M; Altıntoprak, N; Berkoz, M; Cingi, C; Kar, M; Muluk, NB, 2016) |
| "Twenty-eight male Wistar albino rats were randomly divided into four groups: a control group; a group in which allergic rhinitis was induced and no treatment given; a group in which allergic rhinitis was induced followed by treatment with azelastine hydrochloride on days 21-28; and a group in which allergic rhinitis was induced followed by treatment with curcumin on days 21-28." | 3.83 | Can curcumin modulate allergic rhinitis in rats? ( Acar, M; Ada, S; Berkoz, M; Cengiz, BP; Cingi, C; Karimkhani, H; Muluk, NB; Shojaolsadati, P; Yigitaslan, S, 2016) |
| "Azelastine was suggested as a supplementary choice of glucocorticoid for the control of moderate to severe allergic rhinitis (AR)." | 3.81 | Azelastine enhances the clinical efficacy of glucocorticoid by modulating MKP-1 expression in allergic rhinitis. ( Li, H; Li, J; Luo, X; Ma, R; Mou, Z; Wu, X; Xian, D, 2015) |
| "Allergic rhinitis is a frequent presenting problem in primary care in the UK, and has increased in prevalence over the last 30 years." | 2.55 | An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel. ( Lipworth, B; Newton, J; Ram, B; Schwarze, J; Small, I, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (75.00) | 24.3611 |
| 2020's | 7 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Procopiou, PA | 1 |
| Ford, AJ | 1 |
| Gore, PM | 1 |
| Hancock, AP | 1 |
| Hodgson, ST | 1 |
| Holmes, DS | 1 |
| Looker, BE | 1 |
| Vile, S | 1 |
| Clark, KL | 1 |
| Saunders, KA | 1 |
| Slack, RJ | 1 |
| Watts, CJ | 1 |
| Esmaeilzadeh, H | 1 |
| Far, NM | 1 |
| Nabavizadeh, SH | 1 |
| Babaeian, M | 1 |
| Hadipour, M | 1 |
| Alyasin, S | 1 |
| Passali, D | 1 |
| Passali, GC | 1 |
| Damiani, V | 1 |
| Ciprandi, G | 1 |
| Liu, Y | 1 |
| Liu, S | 1 |
| Lu, SF | 1 |
| Zang, GM | 1 |
| Berger, WE | 1 |
| Mustakov, TB | 1 |
| Kralimarkova, TZ | 1 |
| Christoff, G | 1 |
| Popov, TA | 1 |
| Klimek, L | 3 |
| Price, D | 4 |
| Gálffy, G | 1 |
| Emmeluth, M | 1 |
| Koltun, A | 1 |
| Kopietz, F | 1 |
| Nguyen, DT | 2 |
| van Weissenbruch, R | 1 |
| Pohl, W | 1 |
| Kuhl, HC | 2 |
| Scadding, G | 2 |
| Mullol, J | 1 |
| Linton, S | 1 |
| Burrows, AG | 1 |
| Hossenbaccus, L | 1 |
| Ellis, AK | 1 |
| El-Shanawany, T | 1 |
| Ahmed, S | 1 |
| Ray, J | 1 |
| Sargur, R | 1 |
| Kumar, N | 1 |
| Agache, I | 1 |
| Doros, IC | 1 |
| Leru, PM | 1 |
| Bucur, I | 1 |
| Poenaru, M | 1 |
| Sarafoleanu, C | 1 |
| Berger, W | 1 |
| Sher, E | 1 |
| Gawchik, S | 1 |
| Fineman, S | 1 |
| Chu, JT | 1 |
| Kaulsay, R | 1 |
| Haahr, PA | 1 |
| Jacobsen, C | 1 |
| Christensen, ME | 1 |
| Cheng, LH | 1 |
| Lee, JC | 1 |
| Wu, PC | 1 |
| Lin, YY | 1 |
| Chu, YH | 1 |
| Wang, HW | 1 |
| Stjarne, P | 1 |
| Strand, V | 1 |
| Theman, K | 1 |
| Ehnhage, A | 1 |
| Debbaneh, PM | 1 |
| Bareiss, AK | 1 |
| Wise, SK | 1 |
| McCoul, ED | 1 |
| Mösges, R | 1 |
| Braido, F | 1 |
| Sclifò, F | 1 |
| Ferrando, M | 1 |
| Canonica, GW | 2 |
| Luo, X | 1 |
| Ma, R | 1 |
| Wu, X | 1 |
| Xian, D | 1 |
| Li, J | 1 |
| Mou, Z | 1 |
| Li, H | 1 |
| Bousquet, J | 1 |
| Bachert, C | 1 |
| Bernstein, J | 1 |
| Carr, W | 1 |
| Dahl, R | 1 |
| Demoly, P | 2 |
| Devillier, P | 1 |
| Hellings, P | 1 |
| Fokkens, W | 1 |
| Lieberman, P | 1 |
| Meltzer, E | 1 |
| Ryan, D | 1 |
| Wahn, U | 1 |
| Hancı, D | 1 |
| Altun, H | 1 |
| Çetinkaya, EA | 1 |
| Muluk, NB | 3 |
| Cengiz, BP | 2 |
| Cingi, C | 3 |
| Altıntoprak, N | 1 |
| Kar, M | 1 |
| Acar, M | 2 |
| Berkoz, M | 2 |
| Nosulya, EV | 1 |
| Kim, IA | 1 |
| Wu, Y | 1 |
| Liang, F | 1 |
| Yigitaslan, S | 1 |
| Shojaolsadati, P | 1 |
| Karimkhani, H | 1 |
| Ada, S | 1 |
| Lipworth, B | 1 |
| Newton, J | 1 |
| Ram, B | 1 |
| Small, I | 1 |
| Schwarze, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis[NCT01794741] | Phase 3 | 405 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis[NCT05626621] | Phase 4 | 81 participants (Anticipated) | Interventional | 2022-11-23 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
reports of treatment emergent adverse events (NCT01794741)
Timeframe: 3 months of treatment
| Intervention | event (Number) |
|---|---|
| Dymista Nasal Spray | 124 |
| Fluticasone Nasal Spray | 37 |
8 reviews available for azelastine and Allergic Rhinitis
| Article | Year |
|---|---|
Treatment with azelastine hydrochloride and fluticasone propionate in a single delivery device of young children and adolescents with allergic rhinitis.
Topics: Administration, Intranasal; Adolescent; Anti-Allergic Agents; Child; Child, Preschool; Drug Combinat | 2020 |
Future of allergic rhinitis management.
Topics: Allergens; Anti-Allergic Agents; Bifidobacterium; Desensitization, Immunologic; Disease Management; | 2021 |
Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis.
Topics: Administration, Intranasal; Anti-Allergic Agents; Drug Combinations; Fluticasone; Humans; Phthalazin | 2019 |
New therapies for allergic rhinitis.
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Antibodies, Anti-Idiotypic; Antibo | 2014 |
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps.
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Drug Combinations; Humans; Phthala | 2015 |
Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.
Topics: Adrenal Cortex Hormones; Fluticasone; Histamine Antagonists; Humans; Phthalazines; Rhinitis, Allergi | 2016 |
[The modern strategies for the treatment of allergic rhinitis].
Topics: Administration, Intranasal; Drug Combinations; Glucocorticoids; Histamine Antagonists; Humans; Momet | 2016 |
An algorithm recommendation for the pharmacological management of allergic rhinitis in the UK: a consensus statement from an expert panel.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Algorithms; Anti-Allergic Agents; Drug Combinat | 2017 |
2 trials available for azelastine and Allergic Rhinitis
| Article | Year |
|---|---|
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial.
Topics: Acetates; Administration, Intranasal; Adolescent; Adrenal Cortex Hormones; Adult; Asthma; Budesonide | 2022 |
Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial.
Topics: Administration, Intranasal; Anti-Allergic Agents; Child; Child, Preschool; Drug-Related Side Effects | 2018 |
18 other studies available for azelastine and Allergic Rhinitis
| Article | Year |
|---|---|
Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H
Topics: Administration, Intranasal; Animals; Brain; Dogs; Guinea Pigs; Half-Life; Histamine H1 Antagonists; | 2017 |
Azelastine/fluticasone and allergic rhinitis in clinical practice.
Topics: Fluticasone; Humans; Otolaryngology; Phthalazines; Rhinitis, Allergic | 2023 |
Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels.
Topics: Administration, Intranasal; Chemokine CCL26; Double-Blind Method; Humans; Mucins; Nasal Sprays; Rece | 2023 |
For the Patient.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Allergic Agents; Child; Child, Preschool; Drug Combination | 2020 |
Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study.
Topics: Administration, Intranasal; Adult; Comorbidity; Drug Combinations; Female; Fluticasone; Humans; Immu | 2020 |
Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Child; Drug Combinations; Female; Fluticasone; | 2017 |
MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Romania.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Asthmatic Agents; Ch | 2018 |
Histamine H1 receptor gene polymorphism acts as a biological indicator of the prediction of therapeutic efficacy in patients with allergic rhinitis in the Chinese Han population.
Topics: Administration, Oral; Adolescent; Adult; Asthma; Child; China; Environmental Biomarkers; Eosinophil | 2019 |
Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue scale and endoscopy.
Topics: Adolescent; Adult; Aged; Child; Edema; Endoscopy; Female; Fluticasone; Humans; Ireland; Male; Middle | 2018 |
MP-AzeFlu provides rapid and effective allergic rhinitis control: results of a non-interventional study in Denmark.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Inflammatory Agents; Child; Denmark; Drug Combin | 2019 |
Azelastine nasal spray inhibiting sympathetic function on human nasal mucosa in patients with allergy rhinitis.
Topics: Administration, Intranasal; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Humans; Na | 2019 |
Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort.
Topics: Adolescent; Adult; Anti-Asthmatic Agents; Child; Cohort Studies; Fluticasone; Humans; Phthalazines; | 2019 |
All of ARIA in one puff?
Topics: Administration, Intranasal; Androstadienes; Anti-Allergic Agents; Asthma; Clinical Trials as Topic; | 2014 |
Azelastine enhances the clinical efficacy of glucocorticoid by modulating MKP-1 expression in allergic rhinitis.
Topics: Adult; Anti-Inflammatory Agents; Bronchi; Budesonide; Cells, Cultured; Drug Synergism; Dual Specific | 2015 |
Cinnamaldehyde is an effective anti-inflammatory agent for treatment of allergic rhinitis in a rat model.
Topics: Acrolein; Administration, Intranasal; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents; Drug | 2016 |
Antioxidant activities of curcumin in allergic rhinitis.
Topics: Animals; Anti-Allergic Agents; Antioxidants; Biomarkers; Curcumin; Female; Male; Oxidative Stress; P | 2016 |
[Clinical pilot study on the rhinitis due to laryngopharyngeal reflux].
Topics: Benzamides; Esomeprazole; Humans; Laryngopharyngeal Reflux; Morpholines; Phthalazines; Pilot Project | 2016 |
Can curcumin modulate allergic rhinitis in rats?
Topics: Administration, Intranasal; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2016 |